Compound anisodine for opthalmoplegia: a multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004556

Enrollment

Unknown

Registered

2014-04-17

Start date

2014-04-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

opthalmoplegia

Interventions

Treatment group:Compound anisodine

Control group:Vitamin B12

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: We included participants aged 18-75 years with opthalmoplegia. In addition, no compound anisodine was taken within the last month prior to study entry; and informed consent document has been signed.

Exclusion criteria

Exclusion criteria: Exclusion criteria included: etiology of trauma, aneurysm, tumor compression, major stroke, infection, or inflammation; Rejection of compound anisodine therapy; and failed to accept the completion of clinical treatment.

Design outcomes

Primary

Measure	Time frame
Palpebral fissure size;	—

Secondary

Measure	Time frame
Cervical range of motion score;Response rate;Side effect;	—

Countries

China

Contacts

Public ContactWang Tiegang

First affiliated Hospital of Harbin Medical University

tiegangwang2000@163.com+86 0451-53643856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026